InDex Pharmaceuticals will attend the ECCO 2023 congress
InDex Pharmaceuticals announced yesterday that the company will attend the annual congress of the European Crohn’s and Colitis Organisation (ECCO), March 1-4, 2023 in Copenhagen. ECCO is the largest forum for specialists in inflammatory bowel disease globally.
InDex Pharmaceuticals will be present at booth #C3-17 in the exhibition hall at the Bella Center. InDex’s team members will be available on site to provide information about cobitolimod and the ongoing phase III program CONCLUDE, which is evaluating the Toll-like receptor 9 agonist cobitolimod, as a potential novel treatment for moderate to severe left-sided ulcerative colitis. In addition, InDex’s team members will take the opportunity to meet investigators of the Induction 1 study of the CONCLUDE program to discuss study progress with the coordinating Investigator Professor Raja Atreya.
"ECCO is the largest forum for specialists in inflammatory bowel disease in the world and a very significant industry and healthcare professional event,” said Jenny Sundqvist, CEO of InDex Pharmaceuticals. “ECCO provides a great opportunity for the team to further interact with healthcare professionals, potential partners and relevant stakeholders to progress our lead drug candidate cobitolimod and the phase III program CONCLUDE.”
Disclaimer: HC Andersen Capital receives payment from InDex Pharmaceuticals for a DigitalIR/Corporate Visibility agreement. /Claus Thestrup kl. 11.15 d. 28/02-2023
InDex Pharmaceuticals Holding
InDex Pharmaceuticals is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s lead asset is the drug candidate cobitolimod, which is in late-stage clinical development for the treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent-protected discovery stage substances, so-called DNA-based ImmunoModulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases. InDex is based in Stockholm, Sweden. The company’s shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm.
Read more on company page